StockNews.AI
BIOA
StockNews.AI
179 days

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc.(BIOA) Shareholders

1. Class action lawsuit accuses BioAge of securities fraud from its IPO. Investors affected. 2. BioAge halted its STRIDES Phase 2 trial over liver safety concerns. Trial stopped abruptly. 3. Stock plummeted from $20.09 to $4.65 after trial halt. Immediate negative reaction.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit and discontinuation of the lead trial amplify concerns about management and product safety. Similar biotech cases have seen dramatic, rapid price drops when key trials are halted unexpectedly.

How important is it?

The combination of a halted lead product trial and a securities fraud lawsuit signals severe, immediate investor concern. Historical examples in biotech reveal that such events can lead to significant price declines.

Why Short Term?

The immediate legal action and sudden trial discontinuation trigger short-term volatility. Recent history in biotech shows rapid market reactions to adverse trial news.

Related Companies

BIIBVRTXREGN
NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioAge investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=130853&wire=4 BIOA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.  Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024. WHAT'S NEXT? If you suffered a loss in BioAge during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News